203 results
8-K
EX-99.1
CRVO
CervoMed Inc
15 May 24
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
5:06pm
to approximately $1.4 million for the same period in 2023.
Research and Development (R&D) Expenses: R&D expenses for the first quarter of 2024 were approximately
8-K
EX-99.1
g9s0migmmrgw9qnds ow
5 Apr 24
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
4:06pm
8-K
EX-99.1
jcy2sd
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-10.1
f3cv k2m5w4c
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
boby3kk5x
28 Mar 24
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
8:36am
8-K
EX-99.1
dvu36yd
13 Nov 23
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
4:06pm
8-K/A
EX-99.1
e7bly3
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
k1hwpvpvag6f1fb4 1s
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.2
v73862zf
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
55e76m
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
425
EX-99.2
l7fadh67n1q sd
9 Aug 23
Business combination disclosure
4:02pm
425
EX-99.1
kvt6fec2
9 Aug 23
Business combination disclosure
4:02pm
8-K
EX-99.1
8via s8w1j5
9 Aug 23
Other Events
4:02pm
8-K
EX-99.2
9g566
9 Aug 23
Other Events
4:02pm